Aspirin (NSC 27223)

For research use only.

Catalog No.S3017 Synonyms: Acetylsalicylic acid, ASA

16 publications

Aspirin (NSC 27223) Chemical Structure

CAS No. 50-78-2

Aspirin (NSC 27223, Acetylsalicylic acid, ASA) is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin induces autophagy and stimulates mitophagy.

Selleck's Aspirin (NSC 27223) has been cited by 16 publications

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Aspirin (NSC 27223, Acetylsalicylic acid, ASA) is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin induces autophagy and stimulates mitophagy.
Targets
COX2 [1] COX1 [1]
In vitro

Aspirin inhibits the activation of NF-kappa B, thus prevents the degradation of the NF-kappa B inhibitor, I kappa B, and therefore NF-kappa B is retained in the cytosol. Aspirin also inhibits NF-kappa B-dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells. [1] Aspirin and salicylate are mediated in part by their specific inhibition of IKK-beta, thereby preventing activation by NF-kappaB of genes involved in the pathogenesis of the inflammatory response. [2] Aspirin is protective against neurotoxicity elicited by the excitatory amino acid glutamate in rat primary neuronal cultures and hippocampal slices. [3] Aspirin triggers transcellular biosynthesis of a previously unrecognized class of eicosanoidsduring coincubations of human umbilical vein endothelial cells (HUVEC) and neutrophils [polymorphonuclear leukocytes (PMN)]. Aspirin evokes a unique class of eicosanoids formed by acetylated PGHS-2 and 5-lipoxygenase interactions. [4] Aspirin treatment inhibits the phosphorylation of IRS-1 at Ser307 as well as the phosphorylation of JNK, c-Jun, and degradation of IkappaBalpha in 3T3-L1 and Hep G2 cells treated with tumor necrosis factor (TNF)-alpha. Aspirin treatment inhibits phosphorylation of Akt and the mammalian target of rapamycin (but not extracellular regulated kinase or PKCzeta) in response to TNF-alpha. Aspirin rescues insulin-induced glucose uptake in 3T3-L1 adipocytes pretreated with TNF-alpha. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
AGS MYLGeY5kfGmxbjDhd5NigQ>? M2D6PVE2KHSxIE[wJJVud2xxTDDh[pRmeg>? M3LyXVEzKGi{cx?= M3LZ[GlvcGmkaYTpc44hd2ZiRYPjbIVzcWOqaXGgZ49tcS2|dHnteYxifGWmIFnMMVgheHKxZIXjeIlwdiCrbjDoeY1idiCDR2OgZ4VtdHNiYYSgNVUhfG9iNkCgeY1wdC:OIHHmeIVzKDF{IHjyd{BjgSCHTFnTRS=> NEP4fGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG1N|E5Oyd-MkCxOVMyQDN:L3G+
microglia cells Mmq0RY51cW6ndYLvbY5ndGGvbXH0c5J6KGG|c3H5 NH[3cHAyPSCvaX7z MVTBcpRqdmW3cn;pcoZt[W2vYYTvdpkh[WO2aY\peJkhcW5iTGDTMZN1cW23bHH0[YQhemG2IH3pZ5Jw\2yrYTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFCPQT3zeIlufWyjdHXkJHRZSjJicnXs[YF{\SCycnXpcoN2[mG2ZXSg[o9zKDF3IH3pcpMhdWWjc4Xy[YQhPzBibXnud{Bi\nSncjDQUWEh[2ijbHzlcodmNCCLQ{WwQVMvOTMQvF2= NVHoT5JvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVM5PzRpPkKyNVU{QDd2PD;hQi=>
HCT116 MWXGeY5kfGmxbjDhd5NigQ>? NWG3R3N{OSCvTR?= MmnLOkBpenN? MV7Jcohq[mm2aX;uJI9nKFSQRj3hcJBp[S2rbnT1Z4VlKE6ILXvhdJBiSiCjY4TpeoF1cW:wIHnuJIh2dWGwIFjDWFEyPiClZXzsd{BifCBzIH3NJIFnfGW{IE[gbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfS=> NFHrUnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1OFg{PCd-MkKxOVQ5OzR:L3G+
SKBR3 NHzNVI5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV:zNFAhfU1? MYi0PEBpenN? M{G1PWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNMSlJ|IHPlcIx{KGG2IEOwNEB2VSCjZoTldkA1QCCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZk> NIHMXpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS5OFYyPyd-MkK0PVQ3OTd:L3G+
PANC1 MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWDncXBPOzByIIXN M4rR[FQ5KGi{cx?= MYXHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDQRW5EOSClZXzsd{BifCB|MECgeW0h[W[2ZYKgOFghcHK|IHL5JIFt[W2jcjDicJVmKGG|c3H5 Mli5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OUS2NVcoRjJ{NEm0OlE4RC:jPh?=
PC3 NFnBOVRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2Tjc|MxOCC3TR?= MlnFOFghcHK| MXLHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDQR|Mh[2WubIOgZZQhOzByIIXNJIFnfGW{IES4JIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeR?= MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR7NE[xO{c,OjJ2OUS2NVc9N2F-
MDA-MB-231 NYjucGpITnWwY4Tpc44h[XO|YYm= M3[xblExOCC3TR?= M{C4O|MxKG2rboO= MVvJdpJmfmW{c3nicIUhcW6qaXLpeIlwdiCxZjDDU3guOSCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[XKjY3jp[I9vcWNiYXPp[E1qdmS3Y3XkJHBITTJiZn;ycYF1cW:wIHH0JFExOCC3TTDpcoN2[mG2ZXSg[o9zKDNyIH3pcpMh\m:ubH;3[YQh[nliY3;tdI92dmRid3HzbI92fCCvZXHzeZJm\CB|MDDtbY5{KHCxc4SgZZJi[2irZH;ubYMh[WOrZDDjbIFtdGWwZ3WgZpkhemGmaX;pcY12dm:jc4PhfS=> MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ3MUO1PUc,OjN4NUGzOVk9N2F-
THP1 Mo\LSpVv[3Srb36gZZN{[Xl? MVmxNFAhfU1? NETGWHg{OCCvaX7z NVi4SYt2UXK{ZY\ldpNq[mynIHnubIljcXSrb36gc4YhS0:[LUGgbY4hcHWvYX6gWGhROSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIFz[WOqaXTvcolkKGGlaXStbY5lfWOnZDDUXGIzKG[xcn3heIlwdiCjdDCxNFAhfU1iaX7jeYJifGWmIH\vdkA{OCCvaX7zJIZwdGyxd3XkJIJ6KGOxbYDveY5lKHejc3jveZQhdWWjc4Xy[YQhOzBibXnud{Bxd3O2IHHyZYNpcWSxbnnjJIFkcWRiY3jhcIxmdmenIHL5JJJi\GmxaX3teY5w[XO|YYm= M3faRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkWxN|U6Lz5{M{[1NVM2QTxxYU6=
HCT116 NYjVRWs1S3m2b4TvfIlkcXS7IHHzd4F6 NVvQN4ZEPDhiaILz M2nWfmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KE2WVDDhd5NigQ>? Mm\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NUC0NFEoRjJ4N{WwOFAyRC:jPh?=
H9c2 M2DLRWNiemSrb4Dyc5Rm[3SrdnWgZZN{[Xl? M2PKb|EhfU1? NYDvNWZPQCCqcoO= MnjtR4Fz\GmxcILveIVkfGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj5dI95cWFvaX7keYNm\CCxeHnkZZRqfmVic4Ty[ZN{KG2nZHnheIVlKGmwZnzhcY1ifGmxbjDpckBz[XRiSEnjNkBk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDJUE03KGmwIIP1dIVzdmG2YX70JIF1KDFidV2gdJJmcW6ldXLheIVlKG[xcjC4JIhzeyCob3zsc5dm\CCkeTDINm8zKGGmZHn0bY9vKG[xcjCyJIhzeyCkeTDFUGlUSQ>? MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV5NUS3NUc,Ojd3N{W0O|E9N2F-
H9c2 NHXXbZhE[XKmaX;wdo91\WO2aY\lJIF{e2G7 NGGwSngyKHWP M4S5SVghcHK| NGDGZ21E[XKmaX;wdo91\WO2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJlxd3irYT3pcoR2[2WmIH;4bYRifGm4ZTDzeJJme3NibXXkbYF1\WRiaX7mcIFudWG2aX;uJIlvKHKjdDDIPYMzKGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJHRPTi2jbIDoZUBqdiC|dYDldo5ifGGwdDDheEAyKHWPIIDy[Ylv[3WkYYTl[EBnd3JiODDodpMh\m:ubH;3[YQh[nliSELPNkBi\GSrdHnvckBnd3JiMjDodpMhcW5icILld4Vv[2Vib3[gcIVwdnW{aX7lJIJ6KEV? NWjh[ZNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1O|U1PzFpPkK3OVc2PDdzPD;hQi=>
H9c2 NFL3S4RE[XKmaX;wdo91\WO2aY\lJIF{e2G7 MmS5NUB2VQ>? NXXJRZd3QCCqcoO= MVXDZZJlcW:ycn;0[YN1cX[nIHHjeIl3cXS7IHHnZYlve3RiaInwc5hq[S2rbnT1Z4VlKG:6aXTheIl3\SC|dILld5MhcW5icnH0JGg6[zJiY3XscJMh[XO|ZYPz[YQh[XNiYX70bY95cWSjboSgZYN1cX[rdImgZpkhdWWjc4XybY5oKHKnZIXjeIlwdiCrbjDNSGEhdGW4ZXzzJIF1KDFidV2gdJJmcW6ldXLheIVlKG[xcjC4JIhzeyCob3zsc5dm\CCkeTDINm8zKGGmZHn0bY9vKG[xcjCyJIhzeyCkeTDzdIVkfHKxcHjveI9u\XS{eR?= M{GyOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUe1OFcyLz5{N{W3OVQ4OTxxYU6=
H9c2 Ml;VR4Fz\GmxcILveIVkfGm4ZTDhd5NigQ>? NGraT44yKHWP M{ja[lghcHK| MWPDZZJlcW:ycn;0[YN1cX[nIHHjeIl3cXS7IHHnZYlve3RiaInwc5hq[S2rbnT1Z4VlKG:6aXTheIl3\SC|dILld5MhcW5icnH0JGg6[zJiY3XscJMh[XO|ZYPz[YQh[XNiYX70bY95cWSjboSgZYN1cX[rdImgZpkhdWWjc4XybY5oKGmwY4LlZZNmKGmwIGPPSEBi[3Srdnn0fUBifCBzIIXNJJBz\WmwY4XiZZRm\CCob4KgPEBpenNiZn;scI94\WRiYomgTFJQOiCjZHTpeIlwdiCob4KgNkBpenNiYomgd5Bm[3S{b4Doc5RwdWW2com= Mke0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3N{W0O|EoRjJ5NUe1OFcyRC:jPh?=
H9c2 Ml34R4Fz\GmxcILveIVkfGm4ZTDhd5NigQ>? MVexJJVO MVu4JIhzew>? NYDIXVhpS2G{ZHnvdJJwfGWldHn2[UBi[3Srdnn0fUBi\2GrboP0JIh6eG:6aXGtbY5lfWOnZDDvfIll[XSrdnWgd5Rz\XO|IHnuJJJifCCKOXOyJINmdGy|IHHzd4V{e2WmIHHzJIFvfGmxeHnkZY51KGGldHn2bZR6KGK7IH3lZZN2emmwZzDpcoNz\WG|ZTDpckBk[XSjbHHz[UBi[3Srdnn0fUBifCBzIIXNJJBz\WmwY4XiZZRm\CCob4KgPEBpenNiZn;scI94\WRiYomgTFJQOiCjZHTpeIlwdiCob4KgNkBpenNiYomgd5Bm[3S{b4Doc5RwdWW2com= NWLGNo83RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1O|U1PzFpPkK3OVc2PDdzPD;hQi=>
H9c2 MoHMR4Fz\GmxcILveIVkfGm4ZTDhd5NigQ>? NXX4NJlxOSC3TR?= MY[4JIhzew>? M4fkbWNiemSrb4Dyc5Rm[3SrdnWgZYN1cX[rdImgZYdicW6|dDDofZBwgGmjLXnu[JVk\WRib4jp[IF1cX[nIIP0doV{eyCvZXTpZZRm\CCrbn\sZY1u[XSrb36gbY4hemG2IFi5Z|Ih[2WubIOgZZN{\XO|ZXSgZZMhe3WycILld5Nqd25ib3[gWG5HNWGucHjhJIlvKHO3cHXycoF1[W62IHH0JFEhfU1icILlbY5kfWKjdHXkJIZweiB6IHjyd{Bnd2yub4fl[EBjgSCKMl:yJIFl\Gm2aX;uJIZweiB{IHjyd{BjgSCHTFnTRS=> MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV5NUS3NUc,Ojd3N{W0O|E9N2F-
H9c2 M1eybWNiemSrb4Dyc5Rm[3SrdnWgZZN{[Xl? NHqycJMyKHWP MnTLPEBpenN? MnjiR4Fz\GmxcILveIVkfGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj5dI95cWFvaX7keYNm\CCxeHnkZZRqfmVic4Ty[ZN{KG2nZHnheIVlKGmwZnzhcY1ifGmxbjDpckBz[XRiSEnjNkBk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDJUE0y[mW2YTDpckB{fXCncn7heIFvfCCjdDCxJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhQCCqcoOg[o9tdG:5ZXSgZpkhUDKRMjDh[IRqfGmxbjDmc5IhOiCqcoOgZpkhTUyLU1G= NYD6SHRFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1O|U1PzFpPkK3OVc2PDdzPD;hQi=>
H9c2 M3:2[GNiemSrb4Dyc5Rm[3SrdnWgZZN{[Xl? MWGxJJVO MlrhPEBpenN? MWXDZZJlcW:ycn;0[YN1cX[nIHHjeIl3cXS7IHHnZYlve3RiaInwc5hq[S2rbnT1Z4VlKG:6aXTheIl3\SC|dILld5MhcW5icnH0JGg6[zJiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJG1FSSCuZY\lcJMh[XRiMTD1UUBxemWrbnP1ZoF1\WRiZn;yJFghcHK|IH\vcIxwf2WmIHL5JGgzVzJiYXTkbZRqd25iZn;yJFIhcHK|IHnuJJBz\XOnbnPlJI9nKGynb371dolv\SCkeTDzdIVkfHKxcHjveI9u\XS{eR?= M{XIW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUe1OFcyLz5{N{W3OVQ4OTxxYU6=
H9c2 MmnSR4Fz\GmxcILveIVkfGm4ZTDhd5NigQ>? M4fsd|EhfU1? MUe4JIhzew>? NFrV[ndE[XKmaX;wdo91\WO2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJlxd3irYT3pcoR2[2WmIH;4bYRifGm4ZTDzeJJme3NiaX6gdoF1KEh7Y{KgZ4VtdHNiYYPz[ZN{\WRiYYOgZY51cW:6aXThcpQh[WO2aY\peJkh[nlibXXhd5VzcW6pIHnuZ5Jm[XOnIHnuJHNQTCCjY4Tpeol1gSCjdDCxJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhQCCqcoOg[o9tdG:5ZXSgZpkhUDKRMjDh[IRqfGmxbjDmc5IhOiCqcoOgbY4heHKnc3XuZ4Uhd2ZibHXvcpVzcW6nIHL5JJNx\WN? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV5NUS3NUc,Ojd3N{W0O|E9N2F-
H9c2 MYPDZZJlcW:ycn;0[YN1cX[nIHHzd4F6 NXXCTlQ{OSC3TR?= NG\qOIw5KGi{cx?= NEjv[mxE[XKmaX;wdo91\WO2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJlxd3irYT3pcoR2[2WmIH;4bYRifGm4ZTDzeJJme3NibXXkbYF1\WRiaX7mcIFudWG2aX;uJIlvKHKjdDDIPYMzKGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJGlNNTZiaX6gd5Vx\XKwYYThcpQh[XRiMTD1UUBxemWrbnP1ZoF1\WRiZn;yJFghcHK|IH\vcIxwf2WmIHL5JGgzVzJiYXTkbZRqd25iZn;yJFIhcHK|IHnuJJBz\XOnbnPlJI9nKGynb371dolv\SCkeTDFUGlUSQ>? MlL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3N{W0O|EoRjJ5NUe1OFcyRC:jPh?=
H9c2 MVjDZZJlcW:ycn;0[YN1cX[nIHHzd4F6 NGjqRpgyKHWP MUO4JIhzew>? NY\v[JppS2G{ZHnvdJJwfGWldHn2[UBi[3Srdnn0fUBi\2GrboP0JIh6eG:6aXGtbY5lfWOnZDDvfIll[XSrdnWgd5Rz\XO|IH3l[IlifGWmIHnu[oxidW2jdHnvckBqdiC{YYSgTFlkOiClZXzsd{Bie3Onc4Pl[EBieyC|dYDwdoV{e2mxbjDv[kBKVC1zYnX0ZUBqdiC|dYDldo5ifGGwdDDheEAyKHWPIIDy[Ylv[3WkYYTl[EBnd3JiODDodpMh\m:ubH;3[YQh[nliSELPNkBi\GSrdHnvckBnd3JiMjDodpMhcW5icILld4Vv[2Vib3[gcIVwdnW{aX7lJIJ6KEWO NUTsOWJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1O|U1PzFpPkK3OVc2PDdzPD;hQi=>
H9c2 MkDoR4Fz\GmxcILveIVkfGm4ZTDhd5NigQ>? NXTuZXlCOSC3TR?= MkPOPEBpenN? MmHZR4Fz\GmxcILveIVkfGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj5dI95cWFvaX7keYNm\CCleYTveI95cWOrdImgbY4hemG2IFi5Z|Ih[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkh[XRiMTD1UUBxemWrbnP1ZoF1\WRiZn;yJFghcHK|IH\vcIxwf2WmIHL5JGgzVzJiYXTkbZRqd25iZn;yJFIhcHK|IHL5JG1VXCCjc4PhfS=> M4PjcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUe1OFcyLz5{N{W3OVQ4OTxxYU6=
RAW264.7 NEf3XGlCdnSraX7mcIFudWG2b4L5JIF{e2G7 MVfBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJI1wfXOnIGLBW|I3PC55IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhVFCVLXnu[JVk\WRibnn0dolkKG:6aXTlJJBzd2S3Y4Tpc44h[nlibXXhd5VzcW6pIH7peJJqfGViYXPjeY12dGG2aX;uJIJ6KEe{aXXzd{Bu\XSqb3SsJGlEPTB;NEOuNu69VQ>? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV4MUW4Okc,Ojh3NkG1PFY9N2F-
stem cells NUDIbnd[TnWwY4Tpc44h[XO|YYm= MlPJNVAxKHWP NF\w[Gg2KGSjeYO= NGHVW4FKdmS3Y4Tpc44hd2ZiYXTpdI9o\W6nc3nzJIlvKGi3bXHuJIJwdmVibXHydo94NWSncnn2[YQhdWW|ZX7jbJlu[Wxic4TlcUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjZHnwc45m[3SrbjDwdo9lfWO2aX;uJIF1KDFyMDD1UUBu\WG|dYLl[EBwdiCmYYmgOUBqdiCycnXz[Y5k\SCxZjDJSHgh[nliRVzJV2E> MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTN7OES0N{c,Ojl|OUi0OFM9N2F-
DAOY MULxTHRUKGG|c3H5 MlHndWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? NH3JdHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh30 MoTKdWhVWyCjc4PhfS=> MnLhdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqM{CgZ4VtdHN? NGHrNWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 NVLicpU2eUiWUzDhd5NigQ>? M3zjR5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy| MkjuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
peritoneal cells M2PXTWZ2dmO2aX;uJIF{e2G7 NGrwXIY2KGi{cx?= NYm5SZRiUW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EBRT0V{IIDyc4R2[3Srb36gbY4hSzV5Qly2JI1wfXOnIIDldol1d26nYXygZ4VtdHNibXXhd5Vz\WRiYYSgOUBpenNidHnt[UBqdnSnco\hcEBjgSCHTFnTRUwhUUN3ME20MlA5|ryP MlzXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xO|IoRjNyMEC2NVczRC:jPh?=
HCT8 NXnn[2h2SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MVm3NkBpenN? NIrKUIJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFgh[2WubIOgZYZ1\XJiN{KgbJJ{KGmwIIDy[ZNmdmOnIH;mJINqdm6jbXHs[IVpgWSnIHL5JG1VXCCjc4PhfUwhUUN3ME2xOU43|ryP MoLnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{e0PVQoRjNyMEO3OFk1RC:jPh?=
RPMI8226 NXPz[Yo{S2WubDDjfYNt\SCjc4PhfS=> NY\1fW8zOS55IIXN Mlv5OFghcHK| M1q1b2NmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJHJRVUl6MkK2JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNE9IOSCyaHHz[UBifCBzLkegeW0hcW5icILld4Vv[2Vib3[gZo9zfGW8b33pZkBi\nSncjC0PEBpenNiYomgdJJweGmmaYXtJIlw\GmmZT;SUoF{\SC|dHHpcolv\yCkYYPl[EBndG:5IHP5eI9u\XS{aXOgcYV1cG:mIILlcIF1cX[nIITvJIJwenSnen;tbYI> MlHCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB3OUCyOVgoRjNyNUmwNlU5RC:jPh?=
RPMI8226 NH\xT4tE\WyuIHP5Z4xmKGG|c3H5 M{\FfFEvPyC3TR?= M2DXbFQ5KGi{cx?= MoHrR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gVnBOUTh{Mk[gZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IGOgdIhie2ViYYSgNU44KHWPIHnuJJBz\XOnbnPlJI9nKGKxcoTlfo9ucWJiYX\0[ZIhPDhiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUwWk6jc3Wgd5RicW6rbnegZoF{\WRiZnzve{BkgXSxbXX0dolkKG2ndHjv[EBz\WyjdHn2[UB1dyCkb4L0[ZpwdWmk NET0Z5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEW5NFI2QCd-M{C1PVAzPTh:L3G+
RPMI8226 NEDTN45E\WyuIHP5Z4xmKGG|c3H5 MWmxMlchfU1? MYS0PEBpenN? NGHZ[WhE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBTWE2LOEKyOkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iYXPjeY12dGG2aX;uJIF1KEd{L12gdIhie2ViYYSgNU44KHWPIHnuJJBz\XOnbnPlJI9nKGKxcoTlfo9ucWJiYX\0[ZIhPDhiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUwWk6jc3Wgd5RicW6rbnegZoF{\WRiZnzve{BkgXSxbXX0dolkKG2ndHjv[EBz\WyjdHn2[UB1dyCkb4L0[ZpwdWmk MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODV7MEK1PEc,OzB3OUCyOVg9N2F-
HaCaT NWO3eJFbSW62aYD5doV1cWNiYYPzZZk> M2PkOFExOCC3TR?= MVuyJIhzew>? NF\WfW1CdnSrcIny[ZRq[yCjY4Tpeol1gSCrbjDoeY1idiCKYVPhWEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGTOSoFteGijLXnu[JVk\WRiUFfFNkBxem:mdXP0bY9vKGG2IEGwNEB2VSCycnWtbY5kfWKjdHXkJIZweiB{IHjyd{Bj\W[xcnWgWG5H[WyyaHGgd5RqdXWuYYTpc44h\m:{IEK0JIhzeyCkeTDFUGlUSQ>? NWfqPFRwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GzPVMyOjVpPkOxN|k{OTJ3PD;hQi=>
OVCAR5 MnLtSpVv[3Srb36gZZN{[Xl? MWizNFAhfU1idH:gNUBuVQ>? MXm3NkBpenN? MXjJcohq[mm2aX;uJI9nKE6DUGLUJIlvKGi3bXHuJG9XS0GUNTDj[YxteyCjc4Pld5Nm\CCjczDwc5RmdnSrYYTpc44hd2ZiTlHNVHQhcW6qaXLpeI9zKE[NOE[2MYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGK7IH3lZZN2emmwZzDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZZQhOzByIIXNJJRwKDFibV2gbY5kfWKjdHXkJIZweiB5MjDodpMh[nliU2LCJIF{e2G7 MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOU8oRkOqRV3CUFww[T5?
CCRF-CEM NYHR[HpXTnWwY4Tpc44h[XO|YYm= MlqzN{42KG2P MoDaOFghcHK| MknFTY5pcWKrdHnvckBw\iCQQWDSWEBqdiCqdX3hckBES1KILVPFUUBk\WyuczDhd5Nme3OnZDDhd{Bxd3SnboTpZZRqd25ib3[gUmFOWFRiaX7obYJqfG:{IF\LPFY3NWmwZIXj[YQh[XCxcITvd4l{KGK7IH3lZZN2emmwZzDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZZQhOy53IH3NJJBz\XJvaX7jeYJifGWmIIfpeIghUUN3MDDs[ZZmdCCxZjDGT|g3PiCob4KgOFghcHK|IH\vcIxwf2WmIHL5JINwdXCxdX7kJIFl\Gm2aX;uJIFv\CCodYL0bIVz M3vWOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2Nyd-Q3jFUWJNRC:jPh?=
Jurkat NIq3fZlHfW6ldHnvckBie3OjeR?= MkXuN{42KG2P NGqzbI01QCCqcoO= MVrJcohq[mm2aX;uJI9nKE6DUGLUJIlvKGi3bXHuJGp2emujdDDj[YxteyCjc4Pld5Nm\CCjczDwc5RmdnSrYYTpc44hd2ZiTlHNVHQhcW6qaXLpeI9zKE[NOE[2MYlv\HWlZXSgZZBweHSxc3nzJIJ6KG2nYYP1dolv\yC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYYSgN{42KG2PIIDy[ZIucW6ldXLheIVlKHerdHigTWM2OCCuZY\lcEBw\iCIS{i2OkBnd3JiNEigbJJ{KG[xbHzve4VlKGK7IHPvcZBwfW6mIHHk[Il1cW:wIHHu[EBnfXK2aHXyJIk> MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOU8oRkOqRV3CUFww[T5?
ML2 Mn3ESpVv[3Srb36gZZN{[Xl? M1\GdlMvPSCvTR?= M2fXdlQ5KGi{cx?= M{DQbWlvcGmkaYTpc44hd2ZiTlHQVnQhcW5iaIXtZY4hVUx{IHPlcIx{KGG|c3Xzd4VlKGG|IIDveIVvfGmjdHnvckBw\iCQQV3QWEBqdmirYnn0c5IhTkt6Nk[tbY5lfWOnZDDhdI9xfG:|aYOgZpkhdWWjc4XybY5oKHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjdDCzMlUhdU1icILldk1qdmO3YnH0[YQhf2m2aDDJR|UxKGyndnXsJI9nKE[NOE[2JIZweiB2ODDodpMh\m:ubH;3[YQh[nliY3;tdI92dmRiYXTkbZRqd25iYX7kJIZ2enSqZYKgbY5kfQ>? NXTJeVhGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjVxJ{7DbGVOSkx:L3G+
NOMO MUjGeY5kfGmxbjDhd5NigQ>? NEX4S3M{NjVibV2= MYi0PEBpenN? M2TadmlvcGmkaYTpc44hd2ZiTlHQVnQhcW5iaIXtZY4hVk:PTzDj[YxteyCjc4Pld5Nm\CCjczDwc5RmdnSrYYTpc44hd2ZiTlHNVHQhcW6qaXLpeI9zKE[NOE[2MYlv\HWlZXSgZZBweHSxc3nzJIJ6KG2nYYP1dolv\yC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYYSgN{42KG2PIIDy[ZIucW6ldXLheIVlKHerdHigTWM2OCCuZY\lcEBw\iCIS{i2OkBnd3JiNEigbJJ{KG[xbHzve4VlKGK7IHPvcZBwfW6mIHHk[Il1cW:wIHHu[EBnfXK2aHXyJIlv[w>? M1S0PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2Nyd-Q3jFUWJNRC:jPh?=
NB4 NF61fodHfW6ldHnvckBie3OjeR?= NWXTUo1POy53IH3N NIWy[|I1QCCqcoO= NHvVNHVKdmirYnn0bY9vKG:oIF7BVHJVKGmwIHj1cYFvKE6ENDDj[YxteyCjc4Pld5Nm\CCjczDwc5RmdnSrYYTpc44hd2ZiTlHNVHQhcW6qaXLpeI9zKE[NOE[2MYlv\HWlZXSgZZBweHSxc3nzJIJ6KG2nYYP1dolv\yC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYYSgN{42KG2PIIDy[ZIucW6ldXLheIVlKHerdHigTWM2OCCuZY\lcEBw\iCIS{i2OkBnd3JiNEigbJJ{KG[xbHzve4VlKGK7IHPvcZBwfW6mIHHk[Il1cW:wIHHu[EBnfXK2aHXyJIlv[3V? NYjCeld5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjVxJ{7DbGVOSkx:L3G+
NAMALWA NXT6bFNTTnWwY4Tpc44h[XO|YYm= NIPSZlM{NjVibV2= M1PhUFQ5KGi{cx?= M1vDV2lvcGmkaYTpc44hd2ZiTlHQVnQhcW5iaIXtZY4hVkGPQVzXRUBk\WyuczDhd5Nme3OnZDDhd{Bxd3SnboTpZZRqd25ib3[gUmFOWFRiaX7obYJqfG:{IF\LPFY3NWmwZIXj[YQh[XCxcITvd4l{KGK7IH3lZZN2emmwZzDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZZQhOy53IH3NJJBz\XJvaX7jeYJifGWmIIfpeIghUUN3MDDs[ZZmdCCxZjDGT|g3PiCob4KgOFghcHK|IH\vcIxwf2WmIHL5JINwdXCxdX7kJIFl\Gm2aX;uJIFv\CCodYL0bIVz Mn\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlUwLz6FaFXNRmw9N2F-
Daudi M2PucWZ2dmO2aX;uJIF{e2G7 NHPIb5E{NjVibV2= Moj6OFghcHK| NX[2W5BpUW6qaXLpeIlwdiCxZjDORXBTXCCrbjDoeY1idiCGYYXkbUBk\WyuczDhd5Nme3OnZDDhd{Bxd3SnboTpZZRqd25ib3[gUmFOWFRiaX7obYJqfG:{IF\LPFY3NWmwZIXj[YQh[XCxcITvd4l{KGK7IH3lZZN2emmwZzDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZZQhOy53IH3NJJBz\XJvaX7jeYJifGWmIIfpeIghUUN3MDDs[ZZmdCCxZjDGT|g3PiCob4KgOFghcHK|IH\vcIxwf2WmIHL5JINwdXCxdX7kJIFl\Gm2aX;uJIFv\CCodYL0bIVzKGmw M4PzblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2Nyd-Q3jFUWJNRC:jPh?=
Raji M4\sW2Z2dmO2aX;uJIF{e2G7 NE\iVmY{NjVibV2= NGTWN3Q1QCCqcoO= M1mxdWlvcGmkaYTpc44hd2ZiTlHQVnQhcW5iaIXtZY4hWmGsaTDj[YxteyCjc4Pld5Nm\CCjczDwc5RmdnSrYYTpc44hd2ZiTlHNVHQhcW6qaXLpeI9zKE[NOE[2MYlv\HWlZXSgZZBweHSxc3nzJIJ6KG2nYYP1dolv\yC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYYSgN{42KG2PIIDy[ZIucW6ldXLheIVlKHerdHigTWM2OCCuZY\lcEBw\iCIS{i2OkBnd3JiNEigbJJ{KG[xbHzve4VlKGK7IHPvcZBwfW6mIHHk[Il1cW:wIHHu[EBnfXK2aHXyJIlv[w>? MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOU8oRkOqRV3CUFww[T5?
ARH77 MoHESpVv[3Srb36gZZN{[Xl? MUGzMlUhdU1? MUC0PEBpenN? MlnBTY5pcWKrdHnvckBw\iCQQWDSWEBqdiCqdX3hckBCWkh5NzDj[YxteyCjc4Pld5Nm\CCjczDwc5RmdnSrYYTpc44hd2ZiTlHNVHQhcW6qaXLpeI9zKE[NOE[2MYlv\HWlZXSgZZBweHSxc3nzJIJ6KG2nYYP1dolv\yC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYYSgN{42KG2PIIDy[ZIucW6ldXLheIVlKHerdHigTWM2OCCuZY\lcEBw\iCIS{i2OkBnd3JiNEigbJJ{KG[xbHzve4VlKGK7IHPvcZBwfW6mIHHk[Il1cW:wIHHu[EBnfXK2aHXyJIlv MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOU8oRkOqRV3CUFww[T5?
RPMI8226 NUL5fnlHTnWwY4Tpc44h[XO|YYm= Mny2N{42KG2P M17hSFQ5KGi{cx?= MYjJcohq[mm2aX;uJI9nKE6DUGLUJIlvKGi3bXHuJHJRVUl6MkK2JINmdGy|IHHzd4V{e2WmIHHzJJBwfGWwdHnheIlwdiCxZjDORW1RXCCrbnjpZol1d3JiRlu4OlYucW6mdXPl[EBieG:ydH;zbZMh[nlibXXhd5VzcW6pIILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDheEA{NjVibV2gdJJmei2rbnP1ZoF1\WRid3n0bEBKSzVyIHzleoVtKG:oIF\LPFY3KG[xcjC0PEBpenNiZn;scI94\WRiYomgZ49ueG:3bnSgZYRlcXSrb36gZY5lKG[3coTo[ZI> NUnGXXJ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjVxJ{7DbGVOSkx:L3G+
U266 MnrkSpVv[3Srb36gZZN{[Xl? NVToeFBLOy53IH3N MX60PEBpenN? NGH6bnVKdmirYnn0bY9vKG:oIF7BVHJVKGmwIHj1cYFvKFV{Nk[gZ4VtdHNiYYPz[ZN{\WRiYYOgdI91\W62aXH0bY9vKG:oIF7BUXBVKGmwaHnibZRweiCIS{i2Ok1qdmS3Y3XkJIFxd3C2b4Ppd{BjgSCvZXHzeZJqdmdicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHH0JFMvPSCvTTDwdoVzNWmwY4XiZZRm\CC5aYToJGlEPTBibHX2[Ywhd2ZiRlu4OlYh\m:{IES4JIhzeyCob3zsc5dm\CCkeTDjc41xd3WwZDDh[IRqfGmxbjDhcoQh\nW{dHjldkBqdmN? NEPzVXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPS9pPlPoSW1DVDxxYU6=
NAMALWA MmL3SpVv[3Srb36gZZN{[Xl? MonDN|UhdWdxa3e= MmDJOFUh\GG7cx?= M1zXcXBwfGWwdHnheIlwdiCxZjDORW1RXCCrbnjpZol1d3JiMUCgcYcwc2duIHnwJIJq\CCIS{i2Ok1qdmS3Y3XkJIFvfGm2dX3vdkBi[3Srdnn0fUBqdiCqdX3hckBPSU2DTGfBJINmdGy|IIjlco9oemGodHXkJIlvKFOFSVSgcY92e2ViYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hdW:3c3Wgd5Vzfmm4YXygZZQhOzVibXevb4ctKGmyIHLp[EB2eCC2bzC0OUBl[Xm| MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOU8oRkOqRV3CUFww[T5?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
SHH / SMO / GLI1 / Bcl-2 / Foxm1 ; 

PubMed: 28446712     


Western blot analysis showed SHH, SMO, GLI1, Bcl-2 and Foxm1 proteins expression in U87 and T98G cells treated with indicated concentrations of aspirin for 24 h. GAPDH was used as an internal control. 

PubMed: 23741443     


Western blotting revealed that aspirin down-regulated COX1 and COX2 expression in HCC cell lines.

p-AMPKα / AMPKα / p-ACC / ACC; 

PubMed: 26918349     


Western blot analysis of the effects of aspirin on AMPK and ACC phosphorylation.

p-AKT / AKT / p-ERK / ERK ; 

PubMed: 26918349     


Western blot analysis of the effects of aspirin on Akt and ERK1/2 phosphorylation.

MCL-1; 

PubMed: 26918349     


Western blot analysis of the effects of aspirin on MCL-1 expression.

28446712 23741443 26918349
Growth inhibition assay
Cell viability; 

PubMed: 30221683     


The CCK-8 assay results are presented as bar graphs for the antiproliferative effects of aspirin on RA-FLS. (A-C) RA-FLS were treated with (0, DMSO, 1, 2, 5 and 10 mM) aspirin for 12, 24 and 48 h. At each time interval, cell viability was determined by CCK-8 analysis. Data are presented as the means ± SD (error bars) from three independent experiments. Aspirin inhibited the growth of RA-FLS in a dose-dependent manner. (D) Cell proliferation decreased at 12, 24 and 48 h. Data are presented as the means ± SD (error bars) from three independent experiments. *P<0.05, **P<0.01, ***P<0.001 vs. DMSO group. CCK-8: Cell-Counting Kit-8; RA-FLS, rheumatoid arthritis-fibroblast-like synoviocytes; DMSO, dimethyl sulfoxide; SD, standard deviation.

Cell proliferation ; 

PubMed: 28446712     


U87 and T98G cells were treated with indicated concentrations of aspirin and harvested after 24, 48 and 72 h. Cell proliferation was analyzed by CCK-8 assay. 

30221683 28446712

Protocol

Solubility (25°C)

In vitro DMSO 36 mg/mL (199.82 mM)
Water Insoluble
Ethanol ''36 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+PBS
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 180.16
Formula

C9H8O4

CAS No. 50-78-2
Storage powder
in solvent
Synonyms Acetylsalicylic acid, ASA
Smiles CC(=O)OC1=CC=CC=C1C(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04563546 Not yet recruiting Other: Quality Improvement Acute Coronary Syndrome Duke University January 1 2023 Not Applicable
NCT05031455 Not yet recruiting Biological: Dupilumab|Drug: Placebo Aspirin-exacerbated Respiratory Disease Scripps Clinic|University of California San Diego|Regeneron Pharmaceuticals January 1 2022 Phase 2
NCT04308551 Not yet recruiting Drug: Indobufen|Drug: Aspirin Stable Coronary Heart Disease Henan Institute of Cardiovascular Epidemiology December 30 2021 Not Applicable
NCT04974892 Not yet recruiting Diagnostic Test: Blood test Preeclampsia|Neutrophil|Immunology|Pregnancy Queen Mary University of London September 1 2021 --
NCT04811625 Not yet recruiting Drug: PL-ASA Healthy Volunteers PLx Pharma May 2021 Phase 4
NCT04851964 Recruiting Biological: Experimental: Tezepelumab|Other: Placebo Chronic Rhinosinusitis With Nasal Polyps AstraZeneca|Amgen April 22 2021 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

COX Signaling Pathway Map

Related COX Products

Tags: buy Aspirin (NSC 27223) | Aspirin (NSC 27223) supplier | purchase Aspirin (NSC 27223) | Aspirin (NSC 27223) cost | Aspirin (NSC 27223) manufacturer | order Aspirin (NSC 27223) | Aspirin (NSC 27223) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID